Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study
Authors:
- Martin H. BirkhaeuserMBMartin H. Birkhaeuser
- Kurt LippunerKLKurt Lippuner
- 16 October 2004
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 16 (7) , 791-798
Abstract
The aim of this study was to explore the effect of long-term cross-sex hormonal treatment on cortical and trabecular bone mineral density and main biochemical parameters of bone metabolism in transsexuals. Twenty-four male-to-female (M-F) transsexuals and 15 female-to-male (F-M) transsexuals treated with either an antiandrogen in combination with an estrogen or parenteral testosterone were included in this cross-sectional study. BMD was measured by DXA at distal tibial diaphysis (TDIA) and epiphysis (TEPI), lumbar spine (LS), total hip (HIP) and subregions, and whole body (WB) and Z-scores determined for both the genetic and the phenotypic gender. Biochemical parameters of bone turnover, insulin-like growth factor-1 (IGF-1) and sex hormone levels were measured in all patients. M-F transsexuals were significantly older, taller and heavier than F-M transsexuals. They were treated by cross-sex hormones during a median of 12.5 years before inclusion. As compared with female age-matched controls, they showed a significantly higher median Z-score at TDIA and WB (1.7±1.0 and 1.8±1.1, P Z-scores at TEPI, TDIA and WB compared with female age-matched controls (+0.9±0.2 SD, +1.0±0.4 SD and +1.4±0.3 SD, respectively, P<0.0001 for all) and reached normal male levels except at TEPI. They had significantly higher testosterone and IGF-1 levels (p<0.001) than M-F transsexuals. We conclude that in M-F transsexuals, BMD is preserved over a median of 12.5 years under antiandrogen and estrogen combination therapy, while in F-M transsexuals BMD is preserved or, at sites rich in cortical bone, is increased to normal male levels under a median of 7.6 years of androgen treatment in this cross sectional study. IGF-1 could play a role in the mediation of the effect of androgens on bone in F-M transsexuals.Keywords
This publication has 36 references indexed in Scilit:
- A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging MenJournal of Bone and Mineral Research, 1998
- Hormone replacement therapy in the prevention and treatment of osteoporosisOsteoporosis International, 1997
- Sex Steroids and the Acquisition of Bone MassHormone Research, 1997
- The effect of androgen treatment on bone metabolism in female-to-male transsexualsJournal of Bone and Mineral Research, 1996
- Bone mineral density at distal tibia using dual-energy x-ray absorptiometry in normal women and in patients with vertebral osteoporosis or primary hyperparathyroidismJournal of Bone and Mineral Research, 1994
- Predictors of axial and peripheral bone mineral density in healthy children and adolescents, with special attention to the role of pubertyThe Journal of Pediatrics, 1993
- Androgens and aging in menExperimental Gerontology, 1993
- Aging and strength of bone as a structural materialCalcified Tissue International, 1993
- The effect of cross-gender hormonal treatment on bone metabolism in male-to-female transsexualsJournal of Bone and Mineral Research, 1989
- Evidence of Steroid Receptors in Human Osteoblast-Like CellsConnective Tissue Research, 1989